Psoriatic Arthritis Therapeutics
1. Otezla patent expiration
Treatment: Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Use of otezla (apremilast) for the treatment of Read More
OTEZLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6020358 | AMGEN INC | Substituted phenethylsulfones and method of reducing TNFα levels |
Oct, 2018
(7 years ago) | |
| US7893101 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Dec, 2023
(2 years ago) | |
| US7427638 | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Feb, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455536 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 years ago) | |
| US8802717 | AMGEN INC | Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 years ago) | |
| US7208516 | AMGEN INC | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(2 years ago) | |
| US7659302 | AMGEN INC | Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione |
Mar, 2023
(2 years ago) | |
| US9018243 | AMGEN INC | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
Mar, 2023
(2 years ago) | |
| US6962940 | AMGEN INC | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
Mar, 2023
(2 years ago) | |
| US9724330 | AMGEN INC | Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
Mar, 2023
(2 years ago) | |
| US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(8 years from now) | |
| US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(8 years from now) | |
|
US7427638 (Pediatric) | AMGEN INC | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof |
Aug, 2028
(2 years from now) | |
|
US9872854 (Pediatric) | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
Nov, 2034
(8 years from now) | |
|
US10092541 (Pediatric) | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
Nov, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-694) | Sep 23, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
| New Indication(I-803) | Jul 19, 2022 |
| M(M-257) | Apr 10, 2023 |
| New Indication(I-884) | Dec 20, 2024 |
| Orphan Drug Exclusivity(ODE-248) | Jul 19, 2026 |
| M(M-299) | Jul 20, 2026 |
| Pediatric Exclusivity(PED) | Jan 20, 2027 |
| New Patient Population(NPP) | Apr 25, 2027 |
Drugs and Companies using APREMILAST ingredient
NCE-1 date: 20 January, 2026
Market Authorisation Date: 21 March, 2014
Dosage: TABLET
How can I launch a generic of OTEZLA before it's drug patent expiration?
More Information on Dosage
OTEZLA family patents
2. Xeljanz patent expiration
Treatment: Treatment of adult patients with moderately to severely active ulcerative colitis (uc); Treatment of rheumatoid arthritis
XELJANZ's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7301023 | PF PRISM CV | Chiral salt resolution |
Dec, 2020
(5 years ago) | |
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 years ago) | |
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7842699 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US6956041 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US7301023 | PF PRISM CV | Chiral salt resolution |
May, 2022
(3 years ago) | |
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(2 years ago) | |
| US7091208 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
| US7265221 | PF PRISM CV | Pyrrolo[2,3-d]pyrimidine compounds |
Dec, 2020
(5 years ago) | |
|
USRE41783 (Pediatric) | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
| M(M-14) | Feb 21, 2028 |
| Pediatric Exclusivity(PED) | Aug 21, 2028 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 22 August, 2027
Market Authorisation Date: 06 November, 2012
Dosage: TABLET
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents
3. Xeljanz patent
expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(a month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE41783 (Pediatric) | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Jun, 2026
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-135) | Feb 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-780) | May 30, 2021 |
| New Product(NP) | Sep 25, 2023 |
| New Patient Population(NPP) | Sep 25, 2023 |
| New Indication(I-879) | Dec 14, 2024 |
| M(M-14) | Feb 21, 2028 |
| Pediatric Exclusivity(PED) | Aug 21, 2028 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 25 September, 2020
Dosage: SOLUTION
How can I launch a generic of XELJANZ before it's drug patent expiration?
More Information on Dosage
XELJANZ family patents